+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptide and Anticoagulant Drugs Market by Type, by Low Molecular Weight Heparin Type, and by Application: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025

  • ID: 4853801
  • Report
  • August 2019
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers a forecast and an analysis of the peptide and anticoagulant drugs market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the peptide and anticoagulant drugs market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the peptide and anticoagulant drugs market on a global and regional level.

In order to give the users of this report a comprehensive view of the peptide and anticoagulant drugs market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the peptide and anticoagulant drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the peptide and anticoagulant drugs market on a global and regional basis.

The study provides a decisive view of the peptide and anticoagulant drugs market by segmenting it based on type, low molecular weight heparin type, application, and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players operating in the peptide and anticoagulant drugs market are Sun Pharmaceutical Industries, Baxter, HemmoPharma, Celsus, Wockhardt, AmbioPharm, Biofer, Bachem, Pfizer, Abbott Laboratories, Aspen, Eli Lilly, Takeda, Teva, Sanofi, and Novo Nordisk.

This report segments the global peptide and anticoagulant drugs market into:

Global Peptide and Anticoagulant Drugs Market: By Type

  • Antifungal
  • Hormonal
  • Ace Inhibitors
  • Antibiotic
  • Other Drugs

Global Peptide and Anticoagulant Drugs Market: By Low Molecular Weight Heparin Type

  • Heparin Sodium
  • Enoxaparin Sodium
  • Dalteparin Sodium
  • Fondaparinux

Global Peptide and Anticoagulant Drugs Market: By Application

  • Infectious Diseases
  • Gynecology
  • Cancer
  • Diabetes
  • Cardiology
  • Osteoporosis
  • Others

Global Peptide and Anticoagulant Drugs Market: By Region

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Peptide and Anticoagulant Drugs Market Revenue, 2016-2025 (USD Million)
    • 2.2. Global Peptide and Anticoagulant Drugs Market: Snapshot
  • Chapter 3. Peptide and Anticoagulant Drugs Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Peptide and Anticoagulant Drugs Market Drivers: Impact Analysis
      • 3.2.2. Increasing prevalence of chronic diseases
      • 3.2.3. Rising population
      • 3.2.4. Government support
      • 3.2.5. Increasing healthcare expenditure
    • 3.3. Market restraints
      • 3.3.1. Availability of alternative drugs
    • 3.4. Opportunities
      • 3.4.1. Emerging markets
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Low molecular Heparin weight type
      • 3.6.3. Market attractiveness analysis, by Application
      • 3.6.4. Market attractiveness analysis, by Region
  • Chapter 4. Global Peptide and Anticoagulant Drugs Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Peptide and Anticoagulant Drugs Market: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  • Chapter 5. Global Peptide and Anticoagulant Drugs Market - Type Analysis
    • 5.1. Global Peptide and Anticoagulant Drugs Market: type overview
      • 5.1.1. Global Peptide and Anticoagulant Drugs Market Share, by type, 2018 and 2025
    • 5.2. Antifungal
      • 5.2.1. Global Peptide and Anticoagulant Drugs Market for Antifungal, 2016-2025 (USD Million)
    • 5.3. Hormonal
      • 5.3.1. Global Peptide and Anticoagulant Drugs Market for hormonal, 2016-2025 (USD Million)
    • 5.4. Ace inhibitors
      • 5.4.1. Global Peptide and Anticoagulant Drugs Market for Ace inhibitors, 2016-2025 (USD Million)
    • 5.5. Antibiotic
      • 5.5.1. Global Peptide and Anticoagulant Drugs Market for Antibiotic, 2016-2025 (USD Million)
    • 5.6. Other drugs
      • 5.6.1. Global Peptide and Anticoagulant Drugs Market for Other drugs, 2016-2025 (USD Million)
  • Chapter 6. Global Peptide and Anticoagulant Drugs Market - Low Molecular Heparin Type Analysis
    • 6.1. Global Peptide and Anticoagulant Drugs Market: Low molecular Heparin type overview
      • 6.1.1. Global Peptide and Anticoagulant drugs Market Share, by Low molecular Heparin type, 2018 and 2025
    • 6.2. Heparin sodium
      • 6.2.1. Global Peptide and Anticoagulant Drugs Market for Heparin sodium, 2016-2025 (USD Million)
    • 6.3. Enoxaparin Sodium
      • 6.3.1. Global Peptide and Anticoagulant Drugs Market for Enoxaparin sodium, 2016-2025 (USD Million)
    • 6.4. Dalteparin Sodium
      • 6.4.1. Global Peptide and Anticoagulant Drugs Market for Dalteparin Sodium, 2016-2025 (USD Million)
    • 6.5. Fondaparinux
      • 6.5.1. Global Peptide and Anticoagulant Drugs Market for Fondaparinux, 2016-2025 (USD Million)
  • Chapter 7. Global Peptide and Anticoagulant Drugs Market - Application Analysis
    • 7.1. Global Peptide and Anticoagulant Drugs Market: Application overview
      • 7.1.1. Global Peptide and Anticoagulant Drugs Market Share, by Application, 2018 and 2025
    • 7.2. Infectious disease
      • 7.2.1. Global Peptide and Anticoagulant Drugs Market for infectious disease, 2016-2025 (USD Million)
    • 7.3. Gynecology
      • 7.3.1. Global Peptide and Anticoagulant Drugs Market for gynecology, 2016-2025 (USD Million)
    • 7.4. Cancer
      • 7.4.1. Global Peptide and Anticoagulant Drugs Market for cancer, 2016-2025 (USD Million)
    • 7.5. Diabetes
      • 7.5.1. Global Peptide and Anticoagulant Drugs Market for diabetes, 2016-2025 (USD Million)
    • 7.6. Cardiology
      • 7.6.1. Global Peptide and Anticoagulant Drugs Market for cardiology, 2016-2025 (USD Million)
    • 7.7. osteoporosis
      • 7.7.1. Global Peptide and Anticoagulant Drugs Market for osteoporosis 2016-2025 (USD Million)
    • 7.8. Others
      • 7.8.1. Global Peptide and Anticoagulant Drugs Market for Others, 2016-2025 (USD Million)
  • Chapter 8. Global Peptide and Anticoagulant Drugs Market - Regional Analysis
    • 8.1. Global Peptide and Anticoagulant drugs Market: Regional overview
      • 8.1.1. Global Peptide and Anticoagulant drugs Market Share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.2.2. North America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.2.3. North America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.2.4.2. The U.S. Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.2.4.3. The U.S. Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.2.5.2. Rest of North America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.2.5.3. Rest of North America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.3.2. Europe Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.3.3. Europe Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.4.2. Germany Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.4.3. Germany Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.5.2. U.K. Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.6.2. France Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.6.3. France Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest
        • of Europe Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.7.3. Rest
        • of Europe Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.4.2. China Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.4.3. China Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.5.2. Japan Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.5.3. Japan Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.6.2. India Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.6.3. India Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.5.2. Latin America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.5.3. Latin America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.5.4.2. Brazil Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.5.4.3. Brazil Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
  • Chapter 9. Company Profile
    • 9.1. Sun Pharmaceutical Industries
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Baxter
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. HemmoPharma
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Celsus
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. AmbioPharm
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Bachem
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Pfizer
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Abbott Laboratories
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Aspen
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Takeda
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll